Pharmacology Consulting for Early Clinical Development
Led by Dr. Hui Qin Wang, a preclinical pharmacologist with over 20 years of experience at Novartis and EMD Serono. We integrate PK/PD, efficacy, and biomarker data with translational models to inform study design, dose strategy, and IND-ready documentation.
Expertise in oncology pharmacology: PK/PD, biomarker strategy, efficacy modeling, and translational insight for small molecules, biologics, ADCs, and immune cell engagers.
Core Focus Areas
Pharmacology Strategy Development
Customized strategies aligned with mechanism of action. Translational models reduce risk and streamline early development.
Learn more →Preclinical Data Packages
Integrate PK/PD, efficacy, and biomarker data into clear, actionable go/no-go recommendations, including benchmark studies versus competitor or standard-of-care agents.
Learn more →Clinical & Translational Strategy
Dose–response data for FIH dose prediction. PK/PD-informed protocol design and biomarker-guided endpoint selection.
Learn more →